Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Industry

15 Jul 2024

Kathryn Walker: Six Years of Transformative Leadership in Mental Health Care at Revitalist

Kathryn A. Walker, a vanguard psychiatrist and anesthesia provider, and founder of Revitalist, is at the forefront of revolutionizing mental health care. Her latest innovation, Kate NeuroPsych, an AI bot...

By Madison Roberts

Industry

11 Jul 2024

Psychedelic Therapist Training: New Horizons and Opportunities in Psychedelic-Assisted Therapy

As the field of psychedelic therapy gains recognition and acceptance, a new avenue of opportunity is emerging for mental healthcare professionals. Over the past 70 years, psychedelic-assisted therapy has demonstrated...

By Madison Roberts

Culture

10 Jun 2024

Revitalist and Wake Network Launch Psychedelic Retreats for Practitioners and Clients Providing Immersive Therapies and Trainings

Participants will engage in virtual group meetings and one-on-one sessions before arriving at the retreat to prepare using established protocols. The retreats will be conducted in a legal psilocybin setting,...

By Madison Roberts

Industry

3 Jun 2024

The Emerging Landscape of Psychedelic Therapy: Education and Certification

The field of psychedelic therapy is experiencing a resurgence, highlighting the critical need for comprehensive training and certification programs. This article explores diverse training needs, ethical and regulatory considerations, and...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Culture

20 May 2024

Exploring the Psychedelic Frontier: Top Podcasts and Documentaries

From in-depth podcasts to compelling documentaries, there are numerous resources available for those interested in learning about these transformative experiences....

By Madison Roberts

Breaking News

14 May 2024

Advancing Mental Health Treatments: The Strategic Collaboration Between Enveric Biosciences and MindBio Therapeutics

In a groundbreaking move within the pharmaceutical industry, Enveric Biosciences (NASDAQ: ENVB) a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety,...

By Madison Roberts

Breaking News, Press Releases

13 May 2024

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

AbbVie and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research...

By Madison Roberts

Finance

8 May 2024

A Pioneering Push in Cancer Treatment: Enveric Biosciences Advances with Cannabinoid Therapies

Enveric Biosciences, a notable player in biotechnological innovations, has recently announced a significant licensing agreement that might change the landscape of cancer treatment....

By Madison Roberts

Press Releases

8 May 2024

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Enveric Biosciences announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company to exclusively out-license two patent families of Methods for Treating Breast...

By Madison Roberts

Follow us on social

Latest News

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

WordPress Ads